About this role
About the Role
This is a zero-to-one commercial role at an early-stage healthtech AI company building reimbursement automation for interventional specialties. You will own the entire go-to-market motion for medical device OEMs, working directly with the founding team to define the ideal customer profile, close the first enterprise accounts, and shape product-market fit.
What You'll Do
- Source OEM leads and open relationships across market access and reimbursement teams.
- Run discovery sessions to map OEM workflows and identify where the platform fits.
- Develop a clear ideal customer profile and build a repeatable sales playbook from scratch.
- Own OEM accounts from first call through signed contract and ongoing relationship.
- Attend key industry conferences and build community partnerships to expand reach.
- Research opportunities across procurement, market access intelligence, and reimbursement infrastructure.
- Partner with cross-functional teams to translate OEM needs into product and commercialization priorities.
What We're Looking For
- 2 to 7 years of experience working within or alongside medical device companies.
- Direct exposure to reimbursement, market access, or health economics and outcomes research.
- Strong understanding of the OEM ecosystem, including decision-making cycles, budgeting, and how reimbursement risk affects commercial outcomes.
- Experience in endovascular, cardiovascular, or interventional radiology specialties is strongly preferred.
- Cross-functional exposure across market access, reimbursement, supply chain, or R&D.
- Familiarity with the US healthcare system, including payer and coverage dynamics.
- Comfortable actively incorporating AI tools into day-to-day workflows.
- Willing to travel to conferences and meet customers in person as needed.
Compensation & Benefits
Base salary range: $130,000 to $200,000 USD annually , plus meaningful equity. Visa sponsorship is not available.
Location
Hybrid role based in New York City, NY . Candidates located elsewhere in the United States will also be considered, with a preference for major US hubs. In-person availability is expected when needed, along with some travel to industry conferences.